Introducing The Ingenio® EZporator® Electroporation System from The Experts in Transfection
Madison, Wis. (December, 2018) ‒ Recognized as the leader in nucleic acid delivery technologies, Mirus Bio announces the first instrument added to their product portfolio, the Ingenio® EZporator® Electroporation System. The new device is designed to be used with the Ingenio® Electroporation Solution, which is ideal for mammalian and insect cell transfection and has been […]
Gamma Biosciences Announces Sale of Mirus Bio to Merck KGaA, Darmstadt, Germany, for $600 Million
Gamma Biosciences, a life sciences platform established by KKR to address the advanced therapy bioprocessing market, today announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading science and technology company, whereby Merck KGaA, Darmstadt, Germany, will acquire Gamma operating company Mirus Bio for $600 million in cash.
Mirus Bio Named a Top Workplace by the Wisconsin State Journal

Mirus Bio has been named a Top Workplace 2024 by Wisconsin State Journal Top Workplaces. This award is based solely on employee feedback collected from a survey administered by an external organization.
ASGCT 2024

ASGCT24 May 7-11, 2024 Baltimore, MD Learn more about TransIT-VirusGEN and RevIT. Continue the Conversation We’ll be in booth #2017 featuring our TransIT-VirusGEN Transfection Reagent and the RevIT AAV Enhancer. Stop by to find out how our platform can give you 2-4X increase in AAV titer, >50% reduction in cost per dose, and 2X doses produced per bioreactor run!
Mirus Bio Receives ISO 13485:2016 Certification

Mirus Bio Receives ISO 13485:2016 Certification Completion of this comprehensive certification process underscores the quality of the processes used to support the company’s GMP product portfolio MADISON, Wis., January 31, 2024 — Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene therapy production, biopharmaceutical manufacturing, and research applications, today […]
VirusGEN® and RoosterGEM™, a match made for GMP mRNA transfection

Here we highlight some of the exciting results from Mirus’ ongoing collaboration with RoosterBio. Earlier this year, RoosterBio presented a poster at ASGCT and ISCT which showcased using TransIT-VirusGEN® for high-efficiency transfection of mRNA into human mesenchymal stromal cells (hMSCs) cultured in RoosterGEM™ medium. Both VirusGEN® and RoosterGEM™ have GMP formulations available, which allows for rapid implementation into clinical manufacturing processes that require highly qualified reagents.
Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines
The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines Cambridge, Mass. (January 31, 2023) ‒ Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus […]
Mirus Bio Launches RevIT™ AAV Enhancer

Delivers 2-4x increase in AAV titers across many serotypes, cell lines, growth media, and transfection reagents Significantly reduces production costs and doubles the doses that can be produced in a single bioreactor run MADISON, Wis., Aug. 3, 2023 /PRNewswire/ — Mirus Bio, a life sciences company developing innovative solutions for nucleic acid delivery to support cell and gene […]
Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines
The two companies will collaborate to combine industry-leading technologies and tackle the non-viral delivery of highly complex genome engineering materials to help create human cellular medicines Cambridge, Mass. (January 31, 2023) ‒ Kytopen, a biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced a partnership with the pioneering transfection company, Mirus […]
Gamma Biosciences Launches Initiative Through Mirus Bio to Develop Lipid-Polymer Nanocomplexes for In Vivo mRNA Delivery
Menlo Park, CA and Madison, WI (Mar 22, 2022) ‒ Gamma Biosciences, a global life sciences company serving the advanced therapy market, today announced an initiative through its subsidiary Mirus Bio, a leader in nucleic acid delivery technology, to develop novel, highly active lipid-polymer nanocomplexes for therapeutic mRNA delivery in vivo. The newly created initiative within Mirus […]